发明授权
- 专利标题： MODIFICATION OF HEPATITIS B CORE ANTIGEN
- 专利标题（中）： MODIFICATION乙型肝炎核心抗原
-
申请号： EP01943625.2申请日： 2001-06-22
-
公开(公告)号： EP1294893B1公开(公告)日： 2006-03-15
- 发明人: PAGE, Mark , LI, Jing-Li , PUMPENS, Paul Biomedical Research and Study Centre , BORISOVA, Galina, Biomedical Research& Study Ctr.
- 申请人： UCB Pharma Limited
- 申请人地址： 208 Bath Road Slough Berkshire SL1 3WE GB
- 专利权人： UCB Pharma Limited
- 当前专利权人： UCB Pharma Limited
- 当前专利权人地址： 208 Bath Road Slough Berkshire SL1 3WE GB
- 代理机构： Campbell, Patrick John Henry
- 优先权： GB0015308 20000622; GB0024544 20001006
- 国际公布： WO2001098333 20011227
- 主分类号： C12N15/51
- IPC分类号： C12N15/51 ; C07K14/02 ; A61K39/29 ; A61P31/20
摘要：
A protein is provided comprising hepatitis B core antigen (HBcAg) wherein one or more of the four arginine repeats has been deleted, said protein comprising the C-terminal cysteine of HBcAg. The deleted region may be replaced by an epitope from a protein other than HBcAg, in which case the HBcAg acts as a carrier to present the epitope to the immune system. The chimeric protein is useful in prophylactic and therapeutic vaccination of a host, for example against hepatitis B virus.
公开/授权文献
- EP1294893A2 MODIFICATION OF HEPATITIS B CORE ANTIGEN 公开/授权日：2003-03-26
信息查询
IPC分类:
